RegenRx
Case Western Reserve University
10900 Euclid Avenue
Cleveland
Ohio
44106
United States
Tel: 216-444-5757
12 articles about RegenRx
-
In a letter to shareholders, RegeneRx provided a pipeline update for investors Monday, outlining plans to potentially move forward with a new asset in light of development delays.
-
RegenRx Releases Letter To Stockholders
5/17/2016
-
RegenRx And Dimension Therapeutics Add Development Of Treatments For Two Metabolic Diseases To Exclusive License Agreement
4/23/2015
-
RegenRx And G-treeBNT Create Joint Venture To Develop RGN-259 In The U.S.
1/29/2015
-
U.S. Patent Office Significantly Extends The Term Of Three RegenRx Patents
11/3/2014
-
RegenRx Issues $225,000 Convertible Note
4/1/2013
-
RegenRx Release: New Data on Thymosin Beta 4 Reported at Third International Symposium on Thymosins in Health and Disease
3/20/2012
-
RegenRx Issued Major U.S. Heart Patent
1/9/2012
-
RegenRx Answers Questions Regarding Phase 2 Dry Eye Trial
11/4/2011
-
RegenRx Reports New Statistically Significant Data Confirming Repair of Corneal Damage in Dry Eye Model
4/13/2011
-
RegenRx: Two New Research Papers Published on Thymosin Beta 4
10/26/2007
-
RegeneRx Biopharmaceuticals, Inc. Release: New Study Confirms TB4 Improves Cardiovascular Function After Heart Attack; Collaboration With Pharmaceutical Firm Reproduces And Extends Findings Originally Published In Nature
9/11/2006